# Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)

> **NCT00886886** · PHASE1 · COMPLETED · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 16 (actual)

## Conditions studied

- Mood Disorder
- Substance-related Disorders
- Amphetamine-related Disorders

## Interventions

- **DRUG:** MDMA
- **DRUG:** Reboxetine, 8 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00886886
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-12
- **Final completion:** 2010-03
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2013-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00886886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00886886, "Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT00886886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*